Overview
The Cell and Gene Therapy Catapult (CGT Catapult) is an independent UK-based organization advancing cell and gene therapies through bioprocessing, formulation, characterization, and scalable manufacturing solutions. It supports development of viral vectors like rAAV and lentiviral vectors, as well as cell therapies from research to NHS patient access. CGT Catapult collaborates with industry, academia, and healthcare on automation, analytics, and commercialization challenges.
Frequently asked questions
- What capabilities does CGT Catapult offer for gene therapy development?
- CGT Catapult provides bioprocessing, formulation, and characterization for viral vectors including rAAV, lentiviral, and non-viral platforms, focusing on scalability, cost-effectiveness, safety, and regulatory solutions.
- Does CGT Catapult support cell therapy manufacturing?
- Yes, it offers robust processes for autologous and allogeneic cell therapies, including automated robotic platforms and digital testbeds for scalable production.
- What geographies and regulatory support does CGT Catapult provide?
- Primarily UK-based with facilities in multiple locations, it supports ATMP development and commercialization to enable NHS patient access, including regulatory optimization for rAAV and other advanced therapies.